In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nexvet Biopharma Plc. (NASDAQ:NVET) reported that Farallon Capital has picked up 1,046,345 of common stock as of 2017-04-19.
The acquisition brings the aggregate amount owned by Farallon Capital to a total of 1,046,345 representing a 8.7% stake in the company.
For those not familiar with the company, Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
A glance at Nexvet Biopharma Plc. (NASDAQ:NVET)’s key stats reveals a current market capitalization of 77.57 Million based on 11.75 Million shares outstanding and a price at last close of $6.61 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-04, Gearing picked up 9,000 at a purchase price of $3.35. This brings their total holding to 125,903 as of the date of the filing.
On the sell side, the most recent transaction saw Farrell unload 132 shares at a sale price of $3.27. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nexvet Biopharma Plc. (NASDAQ:NVET) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.